Journal
CRITICAL REVIEWS IN BIOTECHNOLOGY
Volume 43, Issue 3, Pages 484-502Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/07388551.2022.2036691
Keywords
Chinese hamster ovary cell; recombinant factor IX; bioprocessing; cell engineering; factor IX production; post-translational modifications
Categories
Ask authors/readers for more resources
Appropriate treatment of Hemophilia B is crucial, and advancements in recombinant technologies have allowed for the production of Factor IX. However, the complex post-translational modifications of Factor IX have posed challenges for large-scale recombinant production. Further research is needed to optimize the production methods.
Appropriate treatment of Hemophilia B is vital for patients' quality of life. Historically, the treatment used was the administration of coagulation Factor IX derived from human plasma. Advancements in recombinant technologies allowed Factor IX to be produced recombinantly. Successful recombinant production has triggered a gradual shift from the plasma derived origins of Factor IX, as it provides extended half-life and expanded production capacity. However, the complex post-translational modifications of Factor IX have made recombinant production at scale difficult. Considerable research has therefore been invested into understanding and optimizing the recombinant production of Factor IX. Here, we review the evolution of recombinant Factor IX production, focusing on recent developments in bioprocessing and cell engineering to control its post-translational modifications in its expression from Chinese Hamster Ovary (CHO) cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available